By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott said today it will provide a companion diagnostic for an investigational cancer therapy being developed by Merck.

Under the terms of the deal, Abbott will use its fluorescence in situ hybridization technology to develop a test to identify deletions of the TP53 gene in cancer patients. The assay will be evaluated in clinical trials for its ability to select the most appropriate patients for Merck's therapy.

Other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.